<DOC>
	<DOCNO>NCT02918019</DOCNO>
	<brief_summary>This Phase IIb , randomize , placebo-controlled , double-blind , multicenter , multi-arm study evaluate efficacy , safety , pharmacokinetic MSTT1041A compare placebo add-on therapy participant severe , uncontrolled asthma receive medium- high-dose inhale corticosteroid ( ICS ) therapy least one follow additional controller medication : long-acting beta-agonists ( LABA ) , leukotriene modifier ( LTM ) , long-acting muscarinic antagonist ( LAMA ) , long-acting theophylline preparation . The total duration study participant approximately 70 week include screening , run-in , treatment , follow-up .</brief_summary>
	<brief_title>A Study Assess Efficacy Safety MSTT1041A Participants With Uncontrolled Severe Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Body mass index ( BMI ) 18 35 kilogram/square meter ( kg/m^2 ) weight &gt; = 40 kg screening Documented physiciandiagnosed asthma On high dose inhale corticosteroid ( ICS ) therapy plus least one additional allow controller medication Forced expiratory volume 1 second ( FEV1 ) 40 % 80 % predict Evidence uncontrolled asthma Use contraceptive measure Diagnosis mimic asthma Diagnosis occupational asthma , aspirinsensitive asthma , asthma chronic obstructive pulmonary disease overlap syndrome , bronchiolitis , determine investigator Pregnant lactating , intend become pregnant study within 20 week last dose MSTT1041A Recent history smoke History evidence substance abuse would pose risk patient safety , interfere conduct study , impact study result Asthma exacerbation within 4 week prior screen Intubation respiratory failure due asthma within 12 month prior screen Comorbid condition may interfere evaluation investigational medicinal product Known sensitivity active substance excipients administer dose Positive pregnancy test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>